FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891909805> ?p ?o ?g. }

• W2891909805 endingPage "1107" @default.
• W2891909805 startingPage "1097" @default.
• W2891909805 abstract "Sulfadoxine-pyrimethamine resistance threatens efficacy of intermittent preventive treatment of malaria during pregnancy, and alternative regimens need to be identified. With the return of chloroquine efficacy in southern Africa, we postulated that chloroquine either as an intermittent therapy or as weekly chemoprophylaxis would be more efficacious than intermittent sulfadoxine-pyrimethamine for prevention of malaria in pregnancy and associated maternal and newborn adverse outcomes.We did an open-label, single-centre, randomised controlled trial at Ndirande Health Centre, Blantyre, in southern Malawi. We enrolled pregnant women (first or second pregnancy) at 20-28 weeks' gestation who were HIV negative. Participants were randomly assigned in a 1:1:1 ratio using a computer-generated list to either intermittent sulfadoxine-pyrimethamine (two doses of 1500 mg sulfadoxine and 75 mg pyrimethamine, 4 weeks apart), intermittent chloroquine (two doses of 600 mg on day 1, 600 mg on day 2, and 300 mg on day 3), or chloroquine prophylaxis (600 mg on day 1 then 300 mg every week). The primary endpoint was placental malaria in the modified intent-to-treat population, which consisted of participants who contributed placental histopathology data at birth. Secondary outcomes included clinical malaria, maternal anaemia, low birthweight, and safety. This trial is registered with ClinicalTrials.gov, number NCT01443130.Between February, 2012, and May, 2014, we enrolled and randomly allocated 900 women, of whom 765 contributed histopathological data and were included in the primary analysis. 108 (14%) women had placental malaria, which was lower than the anticipated prevalence of placental malaria infection. Protection from placental malaria was not improved by chloroquine as either prophylaxis (30 [12%] of 259 had positive histopathology; relative risk [RR] 0·75, 95% CI 0·48-1·17) or intermittent therapy (39 [15%] of 253; RR 1·00, 0·67-1·50) compared with intermittent sulfadoxine-pyrimethamine (39 [15%] of 253). In protocol-specified analyses adjusted for maternal age, gestational age at enrolment, bednet use the night before enrolment, anaemia at enrolment, and malaria infection at enrolment, women taking chloroquine as prophylaxis had 34% lower placental infections than did those allocated intermittent sulfadoxine-pyrimethamine (RR 0·66, 95% CI 0·46-0·95). Clinical malaria was reported in nine women assigned intermittent sulfadoxine-pyrimethamine, four allocated intermittent chloroquine (p=0·26), and two allocated chloroquine prophylaxis (p=0·063). Maternal anaemia was noted in five women assigned intermittent sulfadoxine-pyrimethamine, 15 allocated intermittent chloroquine (p=0·038), and six assigned chloroquine prophylaxis (p>0·99). Low birthweight was recorded for 31 babies born to women allocated intermittent sulfadoxine-pyrimethamine, 29 assigned intermittent chloroquine (p=0·78), and 41 allocated chloroquine prophylaxis (p=0·28). Four women assigned intermittent sulfadoxine-pyrimethamine had adverse events possibly related to study product compared with 94 women allocated intermittent chloroquine (p<0·0001) and 26 allocated chloroquine prophylaxis (p<0·0001). Three women had severe or life-threatening adverse events related to study product, of whom all were assigned intermittent chloroquine (p=0·25).Chloroquine administered as intermittent therapy did not provide better protection from malaria and related adverse effects compared with intermittent sulfadoxine-pyrimethamine in a setting of high resistance to sulfadoxine-pyrimethamine. Chloroquine chemoprophylaxis might provide benefit in protecting against malaria during pregnancy, but studies with larger sample sizes are needed to confirm these results.US National Institutes of Health." @default.
• W2891909805 created "2018-09-27" @default.
• W2891909805 creator A5002908207 @default.
• W2891909805 creator A5010954298 @default.
• W2891909805 creator A5011992996 @default.
• W2891909805 creator A5017702228 @default.
• W2891909805 creator A5023150691 @default.
• W2891909805 creator A5035600540 @default.
• W2891909805 creator A5039965380 @default.
• W2891909805 creator A5042175882 @default.
• W2891909805 creator A5044689293 @default.
• W2891909805 creator A5053776908 @default.
• W2891909805 creator A5055824241 @default.
• W2891909805 creator A5057970778 @default.
• W2891909805 creator A5058927991 @default.
• W2891909805 creator A5060769320 @default.
• W2891909805 creator A5064083855 @default.
• W2891909805 creator A5069552227 @default.
• W2891909805 creator A5069578834 @default.
• W2891909805 creator A5075414717 @default.
• W2891909805 creator A5075488953 @default.
• W2891909805 creator A5080545276 @default.
• W2891909805 date "2018-10-01" @default.
• W2891909805 modified "2023-10-16" @default.
• W2891909805 title "Chloroquine as weekly chemoprophylaxis or intermittent treatment to prevent malaria in pregnancy in Malawi: a randomised controlled trial" @default.
• W2891909805 cites W1001934701 @default.
• W2891909805 cites W148104492 @default.
• W2891909805 cites W1532912772 @default.
• W2891909805 cites W1751106024 @default.
• W2891909805 cites W1963246123 @default.
• W2891909805 cites W1999748946 @default.
• W2891909805 cites W2031057870 @default.
• W2891909805 cites W2033950979 @default.
• W2891909805 cites W2060346392 @default.
• W2891909805 cites W2079926459 @default.
• W2891909805 cites W2098016374 @default.
• W2891909805 cites W2107362807 @default.
• W2891909805 cites W2112669742 @default.
• W2891909805 cites W2133925071 @default.
• W2891909805 cites W2142413219 @default.
• W2891909805 cites W2143713301 @default.
• W2891909805 cites W2145233028 @default.
• W2891909805 cites W2155454387 @default.
• W2891909805 cites W2255581309 @default.
• W2891909805 cites W2294130235 @default.
• W2891909805 cites W2307970348 @default.
• W2891909805 cites W2310319955 @default.
• W2891909805 cites W2473104846 @default.
• W2891909805 cites W2560221876 @default.
• W2891909805 cites W2786033909 @default.
• W2891909805 doi "https://doi.org/10.1016/s1473-3099(18)30415-8" @default.
• W2891909805 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6217965" @default.
• W2891909805 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30195996" @default.
• W2891909805 hasPublicationYear "2018" @default.
• W2891909805 type Work @default.
• W2891909805 sameAs 2891909805 @default.
• W2891909805 citedByCount "27" @default.
• W2891909805 countsByYear W28919098052018 @default.
• W2891909805 countsByYear W28919098052019 @default.
• W2891909805 countsByYear W28919098052020 @default.
• W2891909805 countsByYear W28919098052021 @default.
• W2891909805 countsByYear W28919098052022 @default.
• W2891909805 countsByYear W28919098052023 @default.
• W2891909805 crossrefType "journal-article" @default.
• W2891909805 hasAuthorship W2891909805A5002908207 @default.
• W2891909805 hasAuthorship W2891909805A5010954298 @default.
• W2891909805 hasAuthorship W2891909805A5011992996 @default.
• W2891909805 hasAuthorship W2891909805A5017702228 @default.
• W2891909805 hasAuthorship W2891909805A5023150691 @default.
• W2891909805 hasAuthorship W2891909805A5035600540 @default.
• W2891909805 hasAuthorship W2891909805A5039965380 @default.
• W2891909805 hasAuthorship W2891909805A5042175882 @default.
• W2891909805 hasAuthorship W2891909805A5044689293 @default.
• W2891909805 hasAuthorship W2891909805A5053776908 @default.
• W2891909805 hasAuthorship W2891909805A5055824241 @default.
• W2891909805 hasAuthorship W2891909805A5057970778 @default.
• W2891909805 hasAuthorship W2891909805A5058927991 @default.
• W2891909805 hasAuthorship W2891909805A5060769320 @default.
• W2891909805 hasAuthorship W2891909805A5064083855 @default.
• W2891909805 hasAuthorship W2891909805A5069552227 @default.
• W2891909805 hasAuthorship W2891909805A5069578834 @default.
• W2891909805 hasAuthorship W2891909805A5075414717 @default.
• W2891909805 hasAuthorship W2891909805A5075488953 @default.
• W2891909805 hasAuthorship W2891909805A5080545276 @default.
• W2891909805 hasBestOaLocation W28919098051 @default.
• W2891909805 hasConcept C126322002 @default.
• W2891909805 hasConcept C131872663 @default.
• W2891909805 hasConcept C168563851 @default.
• W2891909805 hasConcept C187212893 @default.
• W2891909805 hasConcept C203014093 @default.
• W2891909805 hasConcept C203092338 @default.
• W2891909805 hasConcept C2776688490 @default.
• W2891909805 hasConcept C2777035104 @default.
• W2891909805 hasConcept C2777199930 @default.
• W2891909805 hasConcept C2777425658 @default.
• W2891909805 hasConcept C2778048844 @default.
• W2891909805 hasConcept C2778301690 @default.
• W2891909805 hasConcept C2779142074 @default.

• next